Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size

DOI record: { "DOI": "10.1016/j.biopha.2020.110825", "ISSN": [ "0753-3322" ], "URL": "http://dx.doi.org/10.1016/j.biopha.2020.110825", "alternative-id": [ "S0753332220310180" ], "article-number": "110825", "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size" }, { "label": "Journal Title", "name": "journaltitle", "value": "Biomedicine & Pharmacotherapy" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.biopha.2020.110825" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2020 Published by Elsevier Masson SAS." } ], "author": [ { "ORCID": "http://orcid.org/0000-0002-8069-9901", "affiliation": [], "authenticated-orcid": false, "family": "Zhao", "given": "Hong", "sequence": "first" }, { "affiliation": [], "family": "Zhu", "given": "Qi", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-5989-0736", "affiliation": [], "authenticated-orcid": false, "family": "Zhang", "given": "Chi", "sequence": "additional" }, { "affiliation": [], "family": "Li", "given": "Jiawen", "sequence": "additional" }, { "affiliation": [], "family": "Wei", "given": "Ming", "sequence": "additional" }, { "affiliation": [], "family": "Qin", "given": "Yuhong", "sequence": "additional" }, { "affiliation": [], "family": "Chen", "given": "Guilin", "sequence": "additional" }, { "affiliation": [], "family": "Wang", "given": "Ke", "sequence": "additional" }, { "affiliation": [], "family": "Yu", "given": "Junhua", "sequence": "additional" }, { "affiliation": [], "family": "Wu", "given": "Zhao", "sequence": "additional" }, { "affiliation": [], "family": "Chen", "given": "Xianxiang", "sequence": "additional" }, { "affiliation": [], "family": "Wang", "given": "Guiqiang", "sequence": "additional" } ], "container-title": "Biomedicine & Pharmacotherapy", "container-title-short": "Biomedicine & Pharmacotherapy", "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.fr", "clinicalkey.jp", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.com", "em-consulte.com", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2020, 9, 30 ] ], "date-time": "2020-09-30T01:24:58Z", "timestamp": 1601429098000 }, "deposited": { "date-parts": [ [ 2024, 1, 22 ] ], "date-time": "2024-01-22T17:31:08Z", "timestamp": 1705944668000 }, "funder": [ { "award": [ "2020YFC0844100", "2020YFC0846800" ], "name": "Chinese COVID-19 scientific research emergency project" }, { "award": [ "2017ZX10203202", "2013ZX10002005" ], "name": "China Mega-Project for Infectious Diseases" }, { "award": [ "2016ZX09101065" ], "name": "China Mega-Project for Innovative Drugs" } ], "indexed": { "date-parts": [ [ 2024, 5, 14 ] ], "date-time": "2024-05-14T09:07:00Z", "timestamp": 1715677620564 }, "is-referenced-by-count": 74, "issued": { "date-parts": [ [ 2021, 1 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 1, 1 ] ], "date-time": "2021-01-01T00:00:00Z", "timestamp": 1609459200000 } }, { "URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2020, 9, 28 ] ], "date-time": "2020-09-28T00:00:00Z", "timestamp": 1601251200000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S0753332220310180?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S0753332220310180?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "110825", "prefix": "10.1016", "published": { "date-parts": [ [ 2021, 1 ] ] }, "published-print": { "date-parts": [ [ 2021, 1 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.1056/NEJMoa2001316", "article-title": "Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia", "author": "Li", "doi-asserted-by": "crossref", "first-page": "1199", "issue": "13", "journal-title": "N. Engl. J. Med.", "key": "10.1016/j.biopha.2020.110825_bib0005", "volume": "382", "year": "2020" }, { "key": "10.1016/j.biopha.2020.110825_bib0010", "unstructured": "http://2019ncov.chinacdc.cn/2019-nCoV/global.html (Accessed 28 May 2020)." }, { "DOI": "10.1001/jama.2020.2648", "article-title": "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention", "author": "Wu", "doi-asserted-by": "crossref", "first-page": "1239", "issue": "13", "journal-title": "JAMA", "key": "10.1016/j.biopha.2020.110825_bib0015", "volume": "323", "year": "2020" }, { "DOI": "10.1016/j.ijantimicag.2020.105954", "article-title": "Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality", "author": "Zhang", "doi-asserted-by": "crossref", "first-page": "105954", "issue": "5", "journal-title": "Int. J. Antimicrob. Agents", "key": "10.1016/j.biopha.2020.110825_bib0020", "volume": "55", "year": "2020" }, { "DOI": "10.1016/j.phrs.2020.104946", "article-title": "Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications", "author": "An", "doi-asserted-by": "crossref", "first-page": "104946", "journal-title": "Pharmacol. Res.", "key": "10.1016/j.biopha.2020.110825_bib0025", "year": "2020" }, { "DOI": "10.1016/j.cytogfr.2020.05.003", "article-title": "The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system", "author": "Coperchini", "doi-asserted-by": "crossref", "journal-title": "Cytokine Growth Factor Rev.", "key": "10.1016/j.biopha.2020.110825_bib0030", "year": "2020" }, { "article-title": "Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients", "author": "Herold", "journal-title": "medRxiv", "key": "10.1016/j.biopha.2020.110825_bib0035", "year": "2020" }, { "article-title": "The role of interleukin-6 in monitoring severe case of coronavirus disease 2019", "author": "Liu", "journal-title": "EMBO Mol. Med.", "key": "10.1016/j.biopha.2020.110825_bib0040", "year": "2020" }, { "key": "10.1016/j.biopha.2020.110825_bib0045", "unstructured": "Instruction of Tocilizumab https://www.gene.com/download/pdf/actemra_prescribing.pdf (Accessed 28 May 2020)." }, { "DOI": "10.1182/blood.V94.7.2217.419k02_2217_2224", "article-title": "Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)", "author": "Winkler", "doi-asserted-by": "crossref", "first-page": "2217", "issue": "7", "journal-title": "Blood", "key": "10.1016/j.biopha.2020.110825_bib0050", "volume": "94", "year": "1999" }, { "DOI": "10.1056/NEJMoa1215134", "article-title": "Chimeric antigen receptor-modified T cells for acute lymphoid leukemia", "author": "Grupp", "doi-asserted-by": "crossref", "first-page": "1509", "issue": "16", "journal-title": "N. Engl. J. Med.", "key": "10.1016/j.biopha.2020.110825_bib0055", "volume": "368", "year": "2013" }, { "article-title": "Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients", "author": "Zhou", "journal-title": "Sci. Rev.", "key": "10.1016/j.biopha.2020.110825_bib0060", "year": "2020" }, { "DOI": "10.1073/pnas.2005615117", "article-title": "Effective treatment of severe COVID-19 patients with tocilizumab", "author": "Xu", "doi-asserted-by": "crossref", "first-page": "10970", "issue": "20", "journal-title": "Proc. Natl. Acad. Sci.", "key": "10.1016/j.biopha.2020.110825_bib0065", "volume": "117", "year": "2020" }, { "DOI": "10.1016/j.antiviral.2013.09.015", "article-title": "Favipiravir (T-705), a novel viral RNA polymerase inhibitor", "author": "Furuta", "doi-asserted-by": "crossref", "first-page": "446", "issue": "2", "journal-title": "Antiviral Res.", "key": "10.1016/j.biopha.2020.110825_bib0070", "volume": "100", "year": "2013" }, { "DOI": "10.1038/s41422-020-0282-0", "article-title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro", "author": "Wang", "doi-asserted-by": "crossref", "first-page": "269", "issue": "3", "journal-title": "Cell Res.", "key": "10.1016/j.biopha.2020.110825_bib0075", "volume": "30", "year": "2020" }, { "DOI": "10.1016/j.eng.2020.03.007", "article-title": "Experimental treatment with Favipiravir for COVID-19: an open-label control study", "author": "Cai", "doi-asserted-by": "crossref", "journal-title": "Engineering", "key": "10.1016/j.biopha.2020.110825_bib0080", "year": "2020" }, { "key": "10.1016/j.biopha.2020.110825_bib0085", "series-title": "Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia", "year": "2020" }, { "DOI": "10.1038/s41577-018-0066-7", "article-title": "Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer", "author": "Jones", "doi-asserted-by": "crossref", "first-page": "773", "issue": "12", "journal-title": "Nat. Rev. Immunol.", "key": "10.1016/j.biopha.2020.110825_bib0090", "volume": "18", "year": "2018" }, { "DOI": "10.1038/ni.3153", "article-title": "IL-6 as a keystone cytokine in health and disease", "author": "Hunter", "doi-asserted-by": "crossref", "first-page": "448", "issue": "5", "journal-title": "Nat. Immunol.", "key": "10.1016/j.biopha.2020.110825_bib0095", "volume": "16", "year": "2015" }, { "DOI": "10.1016/j.cytogfr.2011.02.003", "article-title": "IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer", "author": "Neurath", "doi-asserted-by": "crossref", "first-page": "83", "issue": "2", "journal-title": "Cytokine Growth Factor Rev.", "key": "10.1016/j.biopha.2020.110825_bib0100", "volume": "22", "year": "2011" }, { "DOI": "10.1136/ard.2008.092932", "article-title": "IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial", "author": "Emery", "doi-asserted-by": "crossref", "first-page": "1516", "issue": "11", "journal-title": "Ann. Rheum. Dis.", "key": "10.1016/j.biopha.2020.110825_bib0105", "volume": "67", "year": "2008" }, { "DOI": "10.1002/art.23940", "author": "Genovese", "doi-asserted-by": "crossref", "first-page": "2968", "issue": "10", "journal-title": "Arthritis Rheum.", "key": "10.1016/j.biopha.2020.110825_bib0110", "volume": "58", "year": "2008" }, { "DOI": "10.1586/eci.10.2", "article-title": "The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis", "author": "Jones", "doi-asserted-by": "crossref", "first-page": "189", "issue": "2", "journal-title": "Expert Rev. Clin. Immunol.", "key": "10.1016/j.biopha.2020.110825_bib0115", "volume": "6", "year": "2010" }, { "DOI": "10.1016/S0140-6736(08)60453-5", "article-title": "Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial", "author": "Smolen", "doi-asserted-by": "crossref", "first-page": "987", "issue": "9617", "journal-title": "Lancet", "key": "10.1016/j.biopha.2020.110825_bib0120", "volume": "371", "year": "2008" }, { "DOI": "10.1182/blood-2008-05-155846", "article-title": "Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease", "author": "Nishimoto", "doi-asserted-by": "crossref", "first-page": "3959", "issue": "10", "journal-title": "Blood", "key": "10.1016/j.biopha.2020.110825_bib0125", "volume": "112", "year": "2008" }, { "DOI": "10.1007/s11684-019-0714-8", "article-title": "Management of cytokine release syndrome related to CAR-T cell therapy", "author": "Chen", "doi-asserted-by": "crossref", "first-page": "610", "issue": "5", "journal-title": "Front. Med.", "key": "10.1016/j.biopha.2020.110825_bib0130", "volume": "13", "year": "2019" }, { "DOI": "10.1136/annrheumdis-2020-218479", "article-title": "Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study", "author": "Ramiro", "doi-asserted-by": "crossref", "first-page": "1143", "issue": "9", "journal-title": "Ann. Rheum. Dis.", "key": "10.1016/j.biopha.2020.110825_bib0135", "volume": "79", "year": "2020" }, { "article-title": "Tocilizumab for treatment of mechanically ventilated patients with COVID-19", "author": "Somers", "journal-title": "Clin. Infect. Dis.", "key": "10.1016/j.biopha.2020.110825_bib0140", "year": "2020" }, { "DOI": "10.1136/annrheumdis-2020-218122", "article-title": "Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study", "author": "Della-Torre", "doi-asserted-by": "crossref", "first-page": "1277", "issue": "10", "journal-title": "Ann. Rheum. Dis.", "key": "10.1016/j.biopha.2020.110825_bib0145", "volume": "79", "year": "2020" } ], "reference-count": 29, "references-count": 29, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S0753332220310180" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "volume": "133" }